FDA Should Expand Over-the-Counter Drug Access But Can't Rely on Pharmaceutical Companies
Source: Jeffrey A. Singer. "FDA commissioner says ‘everything should be over the counter.' Don’t count on Big Pharma to lead the way.." February 19, 2026. reason.com
The Gist
The author argues that many prescription drugs should be available over-the-counter, but drug companies won't push for this change because they make more money when drugs require prescriptions and insurance coverage. The FDA and Congress need to take action independently to expand access and lower prices.
Conclusion
The FDA should expand over-the-counter access to many prescription drugs, but cannot depend on pharmaceutical companies to initiate this change due to their financial incentives to maintain prescription-only status
Premises
- Prescription requirements create artificial scarcity that allows pharmaceutical companies to profit from higher prices through insurance reimbursement systems
- When drugs move from prescription to over-the-counter status, prices typically fall dramatically as patients pay cash instead of using insurance
- Many safe drugs remain prescription-only despite being available over-the-counter in other countries, demonstrating that prescription requirements often lack medical justification
- Pharmaceutical companies actively resist or delay OTC switches even when safety data supports the change, as seen with antihistamines and naloxone
- The current system creates perverse incentives where less safe drugs (like first-generation antihistamines) are more accessible than safer alternatives
- Medical professionals and organizations increasingly support removing prescription requirements for many drugs, indicating the gatekeeping adds little medical value
- Congress and the FDA have alternative pathways to expand OTC access without waiting for manufacturer requests, including international reciprocity and inverted evidentiary standards
Assumptions
- Market competition and cash payments lead to lower drug prices than insurance-mediated transactions
- Safety profiles established in other developed countries are transferable to the US market
- Patients can safely self-medicate with many currently prescription-only drugs
- Pharmaceutical companies prioritize profits over public health when making regulatory decisions
- The current FDA approval process for OTC switches is unnecessarily restrictive